{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:25:37Z","timestamp":1792121137076,"version":"4.4.0"},"reference-count":237,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universidad Sim\u00f3n Bol\u00edvar, Vicerrector\u00eda de Investigaci\u00f3n, Extensi\u00f3n e Innovaci\u00f3n, internal funds for research strengthening, Barranquilla, Colombia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Inflammatory lung diseases (ILDs) represent a global public health crisis characterized by escalating prevalence, significant morbidity, and substantial mortality. In response to the complex immunopathogenic mechanisms driving these conditions, novel pharmacological strategies targeting resolution pathways have emerged throughout the discovery of specialized pro-resolving lipid mediator (SPM; resolvins, maresins, and protectins) dysregulation across the ILD spectra, positioning these endogenous molecules as promising therapeutic candidates for modulating maladaptive inflammation and promoting tissue repair. Over the past decade, this paradigm has catalyzed extensive translational research into SPM-based interventions as precision therapeutics for respiratory inflammation. In asthma, they reduce mucus hypersecretion, bronchial hyperreactivity, and airway inflammation, with prenatal SPM exposure potentially lowering offspring disease risk. In COPD, SPMs attenuate amyloid A-driven inflammation, normalizing cytokine\/chemokine imbalances and oxidative stress and mitigating COVID-19-associated cytokine storm, enhancing survival. This review synthesizes SPMs\u2019 pharmacotherapeutic mechanisms in ILDs and evaluates current preclinical and clinical evidence.<\/jats:p>","DOI":"10.3390\/molecules30102212","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T06:31:29Z","timestamp":1747636289000},"page":"2212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Specialized Pro-Resolving Lipid Mediators in Pulmonary Diseases: Molecular and Therapeutic Implications"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7180-4765","authenticated-orcid":false,"given":"\u00c1ngel","family":"Ortega","sequence":"first","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8030-1780","authenticated-orcid":false,"given":"Pablo","family":"Duran","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5522-7697","authenticated-orcid":false,"given":"Bermary","family":"Garrido","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6652-8834","authenticated-orcid":false,"given":"Alexander","family":"Manzano","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Navarro","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5501-0383","authenticated-orcid":false,"given":"Aljadis","family":"Silva","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-8846","authenticated-orcid":false,"given":"Milagros","family":"Rojas","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5480-4608","authenticated-orcid":false,"given":"Juan Bautista","family":"De Sanctis","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palack\u00fd University Olomouc, 77900 Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Radzioch","sequence":"additional","affiliation":[{"name":"The Research Institute of the McGill, University Health Center, McGill University, Montreal, QC H0H H9Z, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2169-3208","authenticated-orcid":false,"given":"Diego","family":"Rivera-Porras","sequence":"additional","affiliation":[{"name":"Universidad de la Costa, Departamento de Productividad e Innovaci\u00f3n, Barranquilla 080001, Atl\u00e1ntico, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-0276","authenticated-orcid":false,"given":"Carlos Silva","family":"Paredes","sequence":"additional","affiliation":[{"name":"Universidad del Zulia, Facultad de Medicina, Departamento de Ciencias Fisiol\u00f3gicas, Maracaibo 4001, Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-8887","authenticated-orcid":false,"given":"Valmore","family":"Berm\u00fadez","sequence":"additional","affiliation":[{"name":"Universidad Sim\u00f3n Bol\u00edvar, Facultad de Ciencias de la Salud, Centro de Investigaciones en Ciencias de la Vida, Barranquilla 080001, Atl\u00e1ntico, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"ref_1","unstructured":"(2022, March 18). Asthma. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma."},{"key":"ref_2","unstructured":"(2022, March 18). Chronic Obstructive Pulmonary Disease (COPD). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd)."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.pcl.2016.04.001","article-title":"Background and Epidemiology","volume":"63","author":"Sanders","year":"2016","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_4","unstructured":"(2024, July 01). COVID-19 Cases | WHO COVID-19 Dashboard. Available online: https:\/\/data.who.int\/dashboards\/covid19\/cases."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/resp.12660","article-title":"Global burden of COPD","volume":"21","author":"Tan","year":"2016","journal-title":"Respirol. Carlton Vic."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1002\/alr.21547","article-title":"Epidemiology and economic burden of asthma","volume":"5","author":"Loftus","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40273-019-00797-2","article-title":"The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective","volume":"37","author":"Frey","year":"2019","journal-title":"PharmacoEconomics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/TA.0000000000001926","article-title":"Health care utilization and the cost of posttraumatic acute respiratory distress syndrome care","volume":"85","author":"Robles","year":"2018","journal-title":"J. Trauma Acute Care Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejphar.2015.11.001","article-title":"DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation","volume":"785","author":"Duvall","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Philippe, R., and Urbach, V. (2018). Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102865"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00281-016-0560-6","article-title":"Key mechanisms governing resolution of lung inflammation","volume":"38","author":"Robb","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"ref_12","first-page":"1119","article-title":"Resolvin D1 prevents smoking-induced emphysema and promotes lung tissue regeneration","volume":"11","author":"Kim","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1503734","article-title":"Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring","volume":"375","author":"Bisgaard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/XEB.0000000000000056","article-title":"The association of dietary intake and supplementation of specific polyunsaturated fatty acids with inflammation and functional capacity in chronic obstructive pulmonary disease: A systematic review","volume":"14","author":"Atlantis","year":"2016","journal-title":"Int. J. Evid. Based Healthc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MPG.0b013e3181b47967","article-title":"Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis","volume":"50","author":"Keen","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.mam.2017.03.005","article-title":"Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors","volume":"58","author":"Chiang","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"ref_17","first-page":"836","article-title":"The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury","volume":"184","author":"Seki","year":"2010","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbrc.2008.01.012","article-title":"Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma","volume":"367","author":"Aoki","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1172\/JCI97943","article-title":"Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators","volume":"128","author":"Serhan","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri2294","article-title":"Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators","volume":"8","author":"Serhan","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1515\/revneuro-2017-0074","article-title":"The roles of special proresolving mediators in pain relief","volume":"29","author":"Zhang","year":"2018","journal-title":"Rev. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.biochi.2009.01.008","article-title":"Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale","volume":"91","author":"Calder","year":"2009","journal-title":"Biochimie"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacl.2017.06.011","article-title":"Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements","volume":"11","author":"Schaller","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_24","first-page":"181","article-title":"Lipoxins: Nature\u2019s way to resolve inflammation","volume":"8","author":"Chandrasekharan","year":"2015","journal-title":"J. Inflamm. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2015.03.083","article-title":"Lipoxins and aspirin-triggered lipoxins in resolution of inflammation","volume":"760","author":"Romano","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15178","DOI":"10.1073\/pnas.0405445101","article-title":"Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial","volume":"101","author":"Chiang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2015.08.049","article-title":"COX-2, aspirin and metabolism of arachidonic, eicosapentaenoic and docosahexaenoic acids and their physiological and clinical significance","volume":"785","author":"Poorani","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2012.04374.x","article-title":"Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?","volume":"75","author":"Calder","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.plefa.2010.02.003","article-title":"Resolvins and protectins: Natural pharmacophores for resolution biology","volume":"82","author":"Levy","year":"2010","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1074\/jbc.M609212200","article-title":"Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation","volume":"282","author":"Sun","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1476-5381.2009.00290.x","article-title":"Resolvins and protectins: Mediating solutions to inflammation","volume":"158","author":"Kohli","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1096\/fj.201800254R","article-title":"Unified nexus of macrophages and maresins in cardiac reparative mechanisms","volume":"32","author":"Jadapalli","year":"2018","journal-title":"FASEB J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2380319","DOI":"10.1155\/2018\/2380319","article-title":"Maresins: Specialized Proresolving Lipid Mediators and Their Potential Role in Inflammatory-Related Diseases","volume":"2018","author":"Tang","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1373\/clinchem.2012.190199","article-title":"Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation","volume":"58","author":"Mas","year":"2012","journal-title":"Clin. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/alr.21609","article-title":"Asthma: Definitions and pathophysiology","volume":"5","author":"Mims","year":"2015","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.bbalip.2014.08.010","article-title":"Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance","volume":"1851","author":"Calder","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1165\/rcmb.2023-0121OC","article-title":"Eosinophil Phenotypes Are Functionally Regulated by Resolvin D2 during Allergic Lung Inflammation","volume":"69","author":"Peh","year":"2023","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"L399","DOI":"10.1152\/ajplung.00070.2023","article-title":"P2X7 signaling influences the production of pro-resolving and pro-inflammatory lipid mediators in alveolar macrophages derived from individuals with asthma","volume":"325","author":"Townsend","year":"2023","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2174\/1568026611109060629","article-title":"Novel anti-inflammatory--pro-resolving mediators and their receptors","volume":"11","author":"Serhan","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.jaci.2016.02.012","article-title":"Could relative abundance of airway lipoxins be the clue to restore corticosteroid sensitivity in severe asthma?","volume":"137","author":"Dauletbaev","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_42","first-page":"3877","article-title":"Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism","volume":"21","author":"Levy","year":"2007","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.physiol.010908.163200","article-title":"Immunobiology of asthma","volume":"71","author":"Hamid","year":"2009","journal-title":"Annu. Rev. Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"174ra26","DOI":"10.1126\/scitranslmed.3004812","article-title":"Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma","volume":"5","author":"Barnig","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.immunol.25.022106.141647","article-title":"Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways","volume":"25","author":"Serhan","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kytikova, O., Novgorodtseva, T., Denisenko, Y., Antonyuk, M., and Gvozdenko, T. (2019). Pro-Resolving Lipid Mediators in the Pathophysiology of Asthma. Med. Kaunas Lith., 55.","DOI":"10.3390\/medicina55060284"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1398-9995.2004.00617.x","article-title":"Lipoxins in asthma: Potential therapeutic mediators on bronchial inflammation?","volume":"59","author":"Bonnans","year":"2004","journal-title":"Allergy"},{"key":"ref_48","first-page":"47","article-title":"Lipoxins: Update and impact of endogenous pro-resolution lipid mediators","volume":"160","author":"Rodgers","year":"2008","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1183\/09059180.00012514","article-title":"Innate immunity is a key factor for the resolution of inflammation in asthma","volume":"24","author":"Barnig","year":"2015","journal-title":"Eur. Respir. Rev. Off. J. Eur. Respir. Soc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2015.02.014","article-title":"Leukotriene C4 induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs","volume":"754","author":"Yonetomi","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.alit.2014.08.003","article-title":"Role of omega-3 fatty acids and their metabolites in asthma and allergic diseases","volume":"64","author":"Miyata","year":"2015","journal-title":"Allergol. Int. Off. J. Jpn. Soc. Allergol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev-physiol-021113-170408","article-title":"Resolution of acute inflammation in the lung","volume":"76","author":"Levy","year":"2014","journal-title":"Annu. Rev. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1172\/JCI97951","article-title":"Key roles for lipid mediators in the adaptive immune response","volume":"128","author":"Duffney","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_54","first-page":"1476","article-title":"Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1n-3\u2009DPA","volume":"25","author":"Tungen","year":"2019","journal-title":"Chem. Weinh. Bergstr. Ger."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.intimp.2016.03.014","article-title":"The anti-inflammatory and pro-resolution effects of aspirin-triggered RvD1 (AT-RvD1) on peripheral blood mononuclear cells from patients with severe asthma","volume":"35","author":"Zambalde","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/eji.201545673","article-title":"Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production","volume":"46","author":"Kim","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.immuni.2014.02.009","article-title":"Proresolving lipid mediators and mechanisms in the resolution of acute inflammation","volume":"40","author":"Buckley","year":"2014","journal-title":"Immunity"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bbalip.2014.08.006","article-title":"Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome","volume":"1851","author":"Serhan","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_59","first-page":"863","article-title":"Cutting edge: Maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation","volume":"194","author":"Krishnamoorthy","year":"2015","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1002\/jcp.27836","article-title":"Immunoresolvents in asthma and allergic diseases: Review and update","volume":"234","author":"Lotfi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Levy, B.D. (2012). Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways. Front. Immunol., 3.","DOI":"10.3389\/fimmu.2012.00390"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/2040622314532862","article-title":"Chronic obstructive pulmonary disease exacerbations: Latest evidence and clinical implications","volume":"5","author":"Qureshi","year":"2014","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2500\/aap.2015.36.3812","article-title":"Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond","volume":"36","author":"May","year":"2015","journal-title":"Allergy Asthma Proc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","article-title":"NHLBI\/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccm.2013.10.004","article-title":"Cellular and molecular mechanisms of chronic obstructive pulmonary disease","volume":"35","author":"Barnes","year":"2014","journal-title":"Clin. Chest Med."},{"key":"ref_66","first-page":"34","article-title":"Chronic obstructive pulmonary disease: An overview","volume":"1","author":"Devine","year":"2008","journal-title":"Am. Health Drug Benefits"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.prostaglandins.2012.09.006","article-title":"Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases","volume":"99","author":"Giudetti","year":"2012","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(11)60988-4","article-title":"New insights into the immunology of chronic obstructive pulmonary disease","volume":"378","author":"Brusselle","year":"2011","journal-title":"Lancet Lond. Engl."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.rmed.2009.10.002","article-title":"Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD","volume":"104","author":"Joo","year":"2010","journal-title":"Respir. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1465-9921-10-48","article-title":"Inhaled steroid\/tobacco smoke particle interactions: A new light on steroid resistance","volume":"10","author":"Invernizzi","year":"2009","journal-title":"Respir. Res."},{"key":"ref_72","first-page":"292","article-title":"Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease","volume":"48","author":"Balode","year":"2012","journal-title":"Med. Kaunas Lith."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hsiao, H.M., Sapinoro, R.E., Thatcher, T.H., Croasdell, A., Levy, E.P., Fulton, R.A., Olsen, K.C., Pollock, S.J., Serhan, C.N., and Phipps, R.P. (2013). A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette smoke-induced lung inflammation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058258"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1073\/pnas.1109382109","article-title":"Serum amyloid A opposes lipoxin A4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease","volume":"109","author":"Bozinovski","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1517\/13543776.2011.551115","article-title":"Neutrophil elastase inhibitors","volume":"21","author":"Groutas","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/jpet.111.182139","article-title":"AZD9668: Pharmacological characterization of a novel oral inhibitor of neutrophil elastase","volume":"339","author":"Stevens","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1165\/rcmb.2012-0462OC","article-title":"Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog","volume":"49","author":"Guilherme","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/mi.2009.141","article-title":"Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4","volume":"3","author":"Pfeffer","year":"2010","journal-title":"Mucosal Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"L888","DOI":"10.1152\/ajplung.00125.2015","article-title":"Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages","volume":"309","author":"Croasdell","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1016\/j.ajpath.2015.08.008","article-title":"Resolvin D1 Reduces Emphysema and Chronic Inflammation","volume":"185","author":"Hsiao","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.13031\/2013.24350","article-title":"Protection against breathing dust: Behavior over time in Californian farmers","volume":"14","author":"Mitchell","year":"2008","journal-title":"J. Agric. Saf. Health"},{"key":"ref_82","first-page":"353ra111","article-title":"Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses","volume":"8","author":"Leuti","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molmed.2008.08.005","article-title":"Arachidonic-acid-derived eicosanoids: Roles in biology and immunopathology","volume":"14","author":"Harizi","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1465-9921-13-101","article-title":"An investigation of the resolution of inflammation (catabasis) in COPD","volume":"13","author":"Noguera","year":"2012","journal-title":"Respir. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","article-title":"The noncanonical NF-\u03baB pathway","volume":"246","author":"Sun","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1084\/jem.20081880","article-title":"Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions","volume":"206","author":"Serhan","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCP.0000000000000520","article-title":"Cystic fibrosis survival: The changing epidemiology","volume":"24","author":"Corriveau","year":"2018","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_88","first-page":"564","article-title":"Cystic Fibrosis","volume":"114","author":"Naehrig","year":"2017","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nut.2018.03.052","article-title":"Cystic fibrosis, body composition, and health outcomes: A systematic review","volume":"55\u201356","author":"Calella","year":"2018","journal-title":"Nutr. Burbank Los Angeles Cty. Calif."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mam.2017.04.003","article-title":"Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation","volume":"58","author":"Duvall","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"ref_92","first-page":"3970","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: Impact on mediators and mechanisms of the inflammatory response","volume":"24","author":"Mattoscio","year":"2010","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/09031936.00106013","article-title":"Reduced 15-lipoxygenase 2 and lipoxin A4\/leukotriene B4 ratio in children with cystic fibrosis","volume":"44","author":"Ringholz","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2017.11.017","article-title":"Resolvin D1 regulates epithelial ion transport and inflammation in cystic fibrosis airways","volume":"17","author":"Ringholz","year":"2018","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"L1053","DOI":"10.1152\/ajplung.00368.2015","article-title":"Lipoxin A4 prevents tight junction disruption and delays the colonization of cystic fibrosis bronchial epithelial cells by Pseudomonas aeruginosa","volume":"310","author":"Higgins","year":"2016","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1074\/jbc.M210294200","article-title":"Lipoxin A4 stimulates a cytosolic Ca2+ increase in human bronchial epithelium","volume":"278","author":"Bonnans","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Verri\u00e8re, V., Higgins, G., Al-Alawi, M., Costello, R.W., McNally, P., Chiron, R., Harvey, B.J., and Urbach, V. (2012). Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037746"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial","volume":"198","author":"Kloster","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/mi.2017.36","article-title":"Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection","volume":"11","author":"Codagnone","year":"2018","journal-title":"Mucosal Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ni1056","article-title":"Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway","volume":"5","author":"Karp","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Recchiuti, A., Mattoscio, D., and Isopi, E. (2019). Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00252"},{"key":"ref_102","first-page":"4444","article-title":"Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation","volume":"197","author":"Colas","year":"2016","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.pmbts.2023.11.007","article-title":"SARS-CoV-2 variant biology and immune evasion","volume":"Volume 202","author":"Zaidi","year":"2024","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Chilamakuri, R., and Agarwal, S. (2021). COVID-19: Characteristics and Therapeutics. Cells, 10.","DOI":"10.3390\/cells10020206"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12967-022-03767-z","article-title":"Innate immunity, cytokine storm, and inflammatory cell death in COVID-19","volume":"20","author":"Karki","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e23066","DOI":"10.1096\/fj.202300396R","article-title":"Cytokine storm associated with severe COVID-19 infections: The potential mitigating role of omega-3 fatty acid triglycerides in the ICU","volume":"37","author":"Driscoll","year":"2023","journal-title":"FASEB J."},{"key":"ref_108","first-page":"6782","article-title":"Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids","volume":"25","author":"Regidor","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"106762","DOI":"10.1016\/j.prostaglandins.2023.106762","article-title":"Specialized pro-resolving lipid mediators and resolution of viral diseases","volume":"168","author":"Ferri","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/EBC20200018","article-title":"Specialized pro-resolving mediator network: An update on production and actions","volume":"64","author":"Chiang","year":"2020","journal-title":"Essays Biochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.freeradbiomed.2022.12.006","article-title":"Decreased oxidative stress and altered urinary oxylipidome by intravenous omega-3 fatty acid emulsion in a randomized controlled trial of older subjects hospitalized for COVID-19","volume":"194","author":"Pawelzik","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"101597","DOI":"10.1016\/j.smim.2022.101597","article-title":"E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition","volume":"59","author":"Serhan","year":"2022","journal-title":"Semin. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Recchiuti, A., Patruno, S., Mattoscio, D., Isopi, E., Pomilio, A., Lamolinara, A., Iezzi, M., Pecce, R., and Romano, M. (2020). Resolvin D1 and D2 reduce SARS-Cov-2-induced inflammation in cystic fibrosis macrophages. bioRxiv, bioRxiv 2020.08.28.255463.","DOI":"10.1101\/2020.08.28.255463"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Dalli, J., and Serhan, C.N. (2017). Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01400"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Navarini, L., Vomero, M., Currado, D., Berardicurti, O., Biaggi, A., Marino, A., Bearzi, P., Corberi, E., Rigon, A., and Arcarese, L. (2023). The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still\u2019s disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148268"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Yasmeen, N., Selvaraj, H., Lakhawat, S.S., Datta, M., Sharma, P.K., Jain, A., Khanna, R., Srinivasan, J., and Kumar, V. (2023). Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators. Biochem. Pharmacol., 209.","DOI":"10.1016\/j.bcp.2023.115437"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cell.2013.02.027","article-title":"The Lipid Mediator Protectin D1 Inhibits Influenza Virus Replication and Improves Severe Influenza","volume":"153","author":"Morita","year":"2013","journal-title":"Cell"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Goc, A., Niedzwiecki, A., and Rath, M. (2021). Polyunsaturated \u03c9-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84850-1"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Balta, M.G., Papathanasiou, E., and Christopoulos, P.F. (2021). Specialized Pro-Resolving Mediators as Potential Regulators of Inflammatory Macrophage Responses in COVID-19. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.632238"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Kumar, V., Yasmeen, N., Chaudhary, A.A., Alawam, A.S., Al-Zharani, M., Suliman Basher, N., Harikrishnan, S., Goud, M.D., Pandey, A., and Lakhawat, S.S. (2023). Specialized pro-resolving lipid mediators regulate inflammatory macrophages: A paradigm shift from antibiotics to immunotherapy for mitigating COVID-19 pandemic. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1104577"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2222.1988.tb02857.x","article-title":"Effect of eicosapentaenoic acid in asthma","volume":"18","author":"Kirsch","year":"1988","journal-title":"Clin. Allergy"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12944-016-0220-9","article-title":"The relationship between omega-3 and smoking habit: A cross-sectional study","volume":"15","author":"Scaglia","year":"2016","journal-title":"Lipids Health Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1476-511X-12-117","article-title":"Modification of the fatty acid composition of the erythrocyte membrane in patients with chronic respiratory diseases","volume":"12","author":"Novgorodtseva","year":"2013","journal-title":"Lipids Health Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0140-6736(93)91594-C","article-title":"Eicosapentaenoic acid in cystic fibrosis: Evidence of a pathogenetic role for leukotriene B4","volume":"342","author":"Lawrence","year":"1993","journal-title":"Lancet Lond. Engl."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12967-021-02795-5","article-title":"The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: A randomized clinical trial","volume":"19","author":"Doaei","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"120489","DOI":"10.1016\/j.lfs.2022.120489","article-title":"The effect of polyunsaturated fatty acids on the severity and mortality of COVID patients: A systematic review","volume":"299","author":"Mazidimoradi","year":"2022","journal-title":"Life Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2012.07.048","article-title":"Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma","volume":"131","author":"Miyata","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1164\/rccm.200410-1413OC","article-title":"Severe Asthma Research Program, National Heart, Lung, and Blood Institute Diminished lipoxin biosynthesis in severe asthma","volume":"172","author":"Levy","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaci.2004.09.038","article-title":"Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound","volume":"115","author":"Vachier","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaci.2013.01.058","article-title":"Exhaled breath condensate eicosanoid levels associate with asthma and its severity","volume":"132","author":"Kazani","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"026001","DOI":"10.1088\/1752-7155\/6\/2\/026001","article-title":"Profile of eicosanoids in breath condensate in asthma and COPD","volume":"6","author":"Fritscher","year":"2012","journal-title":"J. Breath. Res."},{"key":"ref_132","first-page":"141","article-title":"Lipoxin A(4) and 8-isoprostane in the exhaled breath condensate of children hospitalized for status asthmaticus","volume":"13","author":"Hasan","year":"2012","journal-title":"Pediatr. Crit. Care Med. J. Soc. Crit. Care Med. World Fed. Pediatr. Intensive Crit. Care Soc."},{"key":"ref_133","first-page":"161","article-title":"The role of lipoxin A4 in exercise-induced bronchoconstriction in asthma","volume":"45","author":"Tahan","year":"2008","journal-title":"J. Asthma Off. J. Assoc. Care Asthma"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1034\/j.1399-3003.2000.16a08.x","article-title":"Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics","volume":"16","author":"Sanak","year":"2000","journal-title":"Eur. Respir. J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1365-2222.2007.02806.x","article-title":"Lipoxin A4 levels in asthma: Relation with disease severity and aspirin sensitivity","volume":"37","author":"Celik","year":"2007","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2011.03839.x","article-title":"Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma","volume":"41","author":"Yamaguchi","year":"2011","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm748","article-title":"Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4)","volume":"8","author":"Levy","year":"2002","journal-title":"Nat. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mi.2014.116","article-title":"Lipoxin B4 promotes the resolution of allergic inflammation in the upper and lower airways of mice","volume":"8","author":"Karra","year":"2015","journal-title":"Mucosal Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbrc.2010.08.025","article-title":"Protective effect of resolvin E1 on the development of asthmatic airway inflammation","volume":"400","author":"Aoki","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_140","first-page":"805","article-title":"Resolvin E1 promotes resolution of inflammation in a mouse model of an acute exacerbation of allergic asthma","volume":"126","author":"Flesher","year":"2014","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"key":"ref_141","first-page":"1983","article-title":"Resolvin D1 and aspirin-triggered resolvin D1 promote resolution of allergic airways responses","volume":"189","author":"Rogerio","year":"2012","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e88588","DOI":"10.1172\/jci.insight.88588","article-title":"Corticosteroids inhibit anti-IgE activities of specialized proresolving mediators on B cells from asthma patients","volume":"2","author":"Kim","year":"2017","journal-title":"JCI Insight"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ni.1627","article-title":"Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway inflammation","volume":"9","author":"Haworth","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4049\/jimmunol.178.1.496","article-title":"Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness","volume":"178","author":"Levy","year":"2007","journal-title":"J. Immunol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/mi.2015.129","article-title":"Aspirin-triggered resolvin D1 is produced during self-resolving gram-negative bacterial pneumonia and regulates host immune responses for the resolution of lung inflammation","volume":"9","author":"Abdulnour","year":"2016","journal-title":"Mucosal Immunol."},{"key":"ref_146","first-page":"57","article-title":"Maresin-1 reduces airway inflammation associated with acute and repetitive exposures to organic dust","volume":"166","author":"Nordgren","year":"2015","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1017\/S0007114511000328","article-title":"Dietary intake of \u03b1-linolenic acid and low ratio of n-6:n-3 PUFA are associated with decreased exhaled NO and improved asthma control","volume":"106","author":"Barros","year":"2011","journal-title":"Br. J. Nutr."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/j.1365-2222.2004.02032.x","article-title":"A case-control study of dietary and erythrocyte membrane fatty acids in asthma","volume":"34","author":"Broadfield","year":"2004","journal-title":"Clin. Htmlent Glyphamp Asciiamp Exp. Allergy"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1378\/chest.07-0038","article-title":"Low dietary nutrient intakes and respiratory health in adolescents","volume":"132","author":"Burns","year":"2007","journal-title":"Chest"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10654-007-9218-y","article-title":"Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults","volume":"23","author":"Kompauer","year":"2008","journal-title":"Eur. J. Epidemiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1183\/09031936.94.07101821","article-title":"The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES I)","volume":"7","author":"Schwartz","year":"1994","journal-title":"Eur. Respir. J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1378\/chest.129.1.39","article-title":"Protective effect of fish oil supplementation on exercise-induced bronchoconstriction in asthma","volume":"129","author":"Mickleborough","year":"2006","journal-title":"Chest"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1164\/rccm.200303-373OC","article-title":"Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes","volume":"168","author":"Mickleborough","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Adams, S., Lopata, A.L., Smuts, C.M., Baatjies, R., and Jeebhay, M.F. (2018). Relationship between Serum Omega-3 Fatty Acid and Asthma Endpoints. Int. J. Environ. Res. Public. Health, 16.","DOI":"10.3390\/ijerph16010043"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3945\/ajcn.112.041145","article-title":"Intakes of long-chain omega-3 (n-3) PUFAs and fish in relation to incidence of asthma among American young adults: The CARDIA study","volume":"97","author":"Li","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1183\/09031936.00.16586100","article-title":"Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma","volume":"16","author":"Nagakura","year":"2000","journal-title":"Eur. Respir. J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/09031936.98.11020361","article-title":"Effect of dietary intake of omega-3 and omega-6 fatty acids on severity of asthma in children","volume":"11","author":"Hodge","year":"1998","journal-title":"Eur. Respir. J."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/thx.43.2.84","article-title":"Effect of dietary supplementation with fish oil lipids on mild asthma","volume":"43","author":"Arm","year":"1988","journal-title":"Thorax"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/ajrccm\/139.6.1395","article-title":"The effects of dietary supplementation with fish oil lipids on the airways response to inhaled allergen in bronchial asthma","volume":"139","author":"Arm","year":"1989","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2169\/internalmedicine.39.107","article-title":"Effects of dietary supplementation with n-3 fatty acids compared with n-6 fatty acids on bronchial asthma","volume":"39","author":"Okamoto","year":"2000","journal-title":"Intern. Med. Tokyo Jpn."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1164\/ajrccm\/147.5.1138","article-title":"Dietary fish oil effects on seasonal hay fever and asthma in pollen-sensitive subjects","volume":"147","author":"Thien","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_162","first-page":"534","article-title":"Evening primose oil and fish oil are ineffective as supplementary treatment of bronchial asthma","volume":"62","author":"Aro","year":"1989","journal-title":"Ann. Allergy"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1183\/09031936.02.02632001","article-title":"Treatment of asthma with lipid extract of New Zealand green-lipped mussel: A randomised clinical trial","volume":"20","author":"Emelyanov","year":"2002","journal-title":"Eur. Respir. J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000235421","article-title":"Effect of a Fish Oil Diet on Asthma: Results of a 1-Year Double-Blind Study","volume":"95","author":"Dry","year":"1991","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ebch.765","article-title":"Cochrane Review: Dietary marine fatty acids (fish oil) for asthma in adults and children","volume":"6","author":"Thien","year":"2011","journal-title":"Evid.-Based Child Health Cochrane Rev. J."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/all.13764","article-title":"EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis","volume":"74","author":"Venter","year":"2019","journal-title":"Allergy"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.rmed.2013.04.010","article-title":"Marine lipid fraction PCSO-524 (lyprinol\/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma","volume":"107","author":"Mickleborough","year":"2013","journal-title":"Respir. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1365-2222.2010.03503.x","article-title":"Lyprinol reduces inflammation and improves lung function in a mouse model of allergic airways disease","volume":"40","author":"Wood","year":"2010","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","article-title":"Global Initiative for Asthma (GINA) Program The global burden of asthma: Executive summary of the GINA Dissemination Committee report","volume":"59","author":"Masoli","year":"2004","journal-title":"Allergy"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/ppul.20644","article-title":"Prevalence of asthma-like symptoms in young children","volume":"42","author":"Bisgaard","year":"2007","journal-title":"Pediatr. Pulmonol."},{"key":"ref_171","first-page":"409","article-title":"Maternal fish oil supplementation in pregnancy modifies neonatal leukotriene production by cord-blood-derived neutrophils","volume":"113","author":"Prescott","year":"2007","journal-title":"Clin. Sci. Lond. Engl. 1979"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1046\/j.1365-2222.2003.01590.x","article-title":"Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy","volume":"33","author":"Dunstan","year":"2003","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaci.2007.09.018","article-title":"Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women","volume":"121","author":"Hartl","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1515\/JPM.2007.031","article-title":"Consumption of omega3-fatty acids during perinatal life: Role in immuno-modulation and allergy prevention","volume":"35","author":"Renz","year":"2007","journal-title":"J. Perinat. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/thx.2006.074187","article-title":"Maternal food consumption during pregnancy and asthma, respiratory and atopic symptoms in 5-year-old children","volume":"62","author":"Willers","year":"2007","journal-title":"Thorax"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jaci.2003.09.009","article-title":"Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: A randomized, controlled trial","volume":"112","author":"Dunstan","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ajcn\/88.1.167","article-title":"Fish oil intake compared with olive oil intake in late pregnancy and asthma in the offspring: 16 y of registry-based follow-up from a randomized controlled trial","volume":"88","author":"Olsen","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1136\/bmj.e184","article-title":"Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants\u2019 allergies in first year of life: Randomised controlled trial","volume":"344","author":"Palmer","year":"2012","journal-title":"BMJ"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/all.12233","article-title":"Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies","volume":"68","author":"Palmer","year":"2013","journal-title":"Allergy"},{"key":"ref_180","first-page":"827","article-title":"Dietary fatty acid composition during pregnancy and the risk of asthma in the offspring","volume":"22","author":"Lumia","year":"2011","journal-title":"Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3945\/ajcn.115.111104","article-title":"Omega-3 long-chain PUFA intake during pregnancy and allergic disease outcomes in the offspring: A systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"103","author":"Best","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2016.02.042","article-title":"Fish oil supplementation during pregnancy and allergic respiratory disease in the adult offspring","volume":"139","author":"Hansen","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_183","first-page":"505","article-title":"Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation","volume":"22","author":"Furuhjelm","year":"2011","journal-title":"Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e20154443","DOI":"10.1542\/peds.2015-4443","article-title":"Prenatal Fish Oil Supplementation and Allergy: 6-Year Follow-up of a Randomized Controlled Trial","volume":"137","author":"Best","year":"2016","journal-title":"Pediatrics"},{"key":"ref_185","first-page":"CD010085","article-title":"Maternal prenatal and\/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood","volume":"7","author":"Gunaratne","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/01.CIR.94.5.952","article-title":"Fish Intake May Limit the Increase in Risk of Coronary Heart Disease Morbidity and Mortality Among Heavy Smokers: The Honolulu Heart Program","volume":"94","author":"Rodriguez","year":"1996","journal-title":"Circulation"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJM199407283310403","article-title":"Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators","volume":"331","author":"Shahar","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.2147\/COPD.S142237","article-title":"Dietary nutrients associated with preservation of lung function in Hispanic and non-Hispanic white smokers from New Mexico","volume":"12","author":"Leng","year":"2017","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ejcn.2010.68","article-title":"Assessment of dietary fat intake and innate immune activation as risk factors for impaired lung function","volume":"64","author":"Wood","year":"2010","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3923\/pjbs.2012.501.505","article-title":"Nutritional evaluation in chronic obstructive pulmonary disease patients","volume":"15","author":"Ahmadi","year":"2012","journal-title":"Pak. J. Biol. Sci. PJBS"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/thx.2004.030858","article-title":"Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease","volume":"60","author":"Broekhuizen","year":"2005","journal-title":"Thorax"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jnutbio.2011.04.005","article-title":"Association between \u03a93 and \u03a96 fatty acid intakes and serum inflammatory markers in COPD","volume":"23","author":"Sauleda","year":"2012","journal-title":"J. Nutr. Biochem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.rmed.2010.05.008","article-title":"Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD","volume":"104","author":"Sugawara","year":"2010","journal-title":"Respir. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.rmed.2012.07.001","article-title":"Effect of anti-inflammatory supplementation with whey peptide and exercise therapy in patients with COPD","volume":"106","author":"Sugawara","year":"2012","journal-title":"Respir. Med."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Lemoine, S.C.M., Brigham, E.P., Woo, H., Hanson, C.K., McCormack, M.C., Koch, A., Putcha, N., and Hansel, N.N. (2019). Omega-3 fatty acid intake and prevalent respiratory symptoms among U.S. adults with COPD. BMC Pulm. Med., 19.","DOI":"10.1186\/s12890-019-0852-4"},{"key":"ref_196","unstructured":"National Institutes of Health (2024, August 22). National Institute on Minority Health and Health Disparities (NIMHD). The National Institute on Minority Health and Health Disparities Research Framework. NIMHD Research Framework, Available online: https:\/\/www.nih.gov\/."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"6567578","DOI":"10.1155\/2018\/6567578","article-title":"Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease","volume":"2018","author":"Shi","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/rccm.201304-0733OC","article-title":"Cigarette Smoke Induces Systemic Defects in Cystic Fibrosis Transmembrane Conductance Regulator Function","volume":"188","author":"Raju","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1164\/rccm.201502-0396LE","article-title":"Recovery of Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction after Smoking Cessation","volume":"192","author":"Courville","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"L811","DOI":"10.1152\/ajplung.00408.2010","article-title":"Critical role of CFTR-dependent lipid rafts in cigarette smoke-induced lung epithelial injury","volume":"300","author":"Bodas","year":"2011","journal-title":"Am. J. Physiol.-Lung Cell. Mol. Physiol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2101581","DOI":"10.1183\/13993003.01581-2021","article-title":"Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction","volume":"60","author":"Kaza","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1086\/675989","article-title":"Loss of Cystic Fibrosis Transmembrane Conductance Regulator Impairs Lung Endothelial Cell Barrier Function and Increases Susceptibility to Microvascular Damage from Cigarette Smoke","volume":"4","author":"Brown","year":"2014","journal-title":"Pulm. Circ."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.83.23.9202","article-title":"Pathological regulation of arachidonic acid release in cystic fibrosis: The putative basic defect","volume":"83","author":"Strandvik","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1203\/00006450-198501000-00028","article-title":"Fatty Acid Abnormalities in Cystic Fibrosis","volume":"19","author":"Farrell","year":"1985","journal-title":"Pediatr. Res."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1194\/jlr.M700388-JLR200","article-title":"Cell culture models demonstrate that CFTR dysfunction leads to defective fatty acid composition and metabolism","volume":"49","author":"Andersson","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1165\/rcmb.2007-0036OC","article-title":"Fenretinide Corrects Newly Found Ceramide Deficiency in Cystic Fibrosis","volume":"38","author":"Guilbault","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2008-0279OC","article-title":"Cystic Fibrosis Fatty Acid Imbalance Is Linked to Ceramide Deficiency and Corrected by Fenretinide","volume":"41","author":"Guilbault","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1007\/s00018-020-03530-x","article-title":"The role of essential fatty acids in cystic fibrosis and normalizing effect of fenretinide","volume":"77","author":"Dumut","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Gari\u0107, D., De Sanctis, J.B., Dumut, D.C., Shah, J., Pe\u00f1a, M.J., Youssef, M., Petrof, B.J., Kopriva, F., Hanrahan, J.W., and Hajduch, M. (2020). Fenretinide favorably affects mucins (MUC5AC\/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction. Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids, 1865.","DOI":"10.1016\/j.bbalip.2019.158538"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Centorame, A., Dumut, D.C., Youssef, M., Ondra, M., Kianicka, I., Shah, J., Paun, R.A., Ozdian, T., Hanrahan, J.W., and Gusev, E. (2022). Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.876842"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1194\/jlr.R800042-JLR200","article-title":"Cyclooxygenases: Structural and functional insights","volume":"50","author":"Rouzer","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.2820055","article-title":"Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects","volume":"237","author":"Samuelsson","year":"1987","journal-title":"Science"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMoa021218","article-title":"Association of cystic fibrosis with abnormalities in fatty acid metabolism","volume":"350","author":"Freedman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Jeanson, L., Guerrera, I.C., Papon, J.-F., Chhuon, C., Zadigue, P., Pruli\u00e8re-Escabasse, V., Amselem, S., Escudier, E., Coste, A., and Edelman, A. (2014). Proteomic analysis of nasal epithelial cells from cystic fibrosis patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108671"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Eickmeier, O., Fussbroich, D., Mueller, K., Serve, F., Smaczny, C., Zielen, S., and Schubert, R. (2017). Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171249"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nature08541","article-title":"Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis","volume":"461","author":"Spite","year":"2009","journal-title":"Nature"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.plefa.2016.03.014","article-title":"The clinical benefits of long-term supplementation with omega-3 fatty acids in cystic fibrosis patients\u2014A pilot study","volume":"108","author":"Hanssens","year":"2016","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0022-3476(94)70362-0","article-title":"Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects","volume":"124","author":"Henderson","year":"1994","journal-title":"J. Pediatr."},{"key":"ref_219","first-page":"418","article-title":"Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo-controlled trial","volume":"25","author":"Panchaud","year":"2006","journal-title":"Clin. Nutr. Edinb. Scotl."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Oliver, C., and Watson, H. (2016). Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst. Rev., CD002201.","DOI":"10.1002\/14651858.CD002201.pub5"},{"key":"ref_221","first-page":"CD002201","article-title":"Omega-3 fatty acid supplementation for cystic fibrosis","volume":"4","author":"Watson","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cts.12428","article-title":"Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis","volume":"10","author":"Elborn","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cct.2018.07.014","article-title":"EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis\u2014Study design and patient demographics","volume":"72","author":"Elborn","year":"2018","journal-title":"Contemp. Clin. Trials"},{"key":"ref_224","first-page":"1503","article-title":"Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4","volume":"23","author":"Zurier","year":"2009","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpt.980","article-title":"Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation","volume":"104","author":"Motwani","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_226","first-page":"S90","article-title":"126 A phase 1 clinical study of CTX-4430 in cystic fibrosis patients","volume":"14","author":"Springman","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_227","unstructured":"(2017). A double-blind, placebo-controlled phase 2 study in adults with cystic fibrosis of anabasum, a selective cannabinoid receptor type 2 agonist. Pediatr. Pulmonol., 52, S214\u2013S516."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2020.09.008","article-title":"Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis","volume":"20","author":"Chmiel","year":"2021","journal-title":"J. Cyst. Fibros"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1569-1993(17)30160-1","article-title":"WS01.5 A Phase 2 study of the safety, pharmacokinetics, and efficacy of anabasum (JBT-101) in cystic fibrosis (CF)","volume":"16","author":"Chmiel","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.1128\/JVI.00553-10","article-title":"Lethal Dissemination of H5N1 Influenza Virus Is Associated with Dysregulation of Inflammation and Lipoxin Signaling in a Mouse Model of Infection","volume":"84","author":"Cilloniz","year":"2010","journal-title":"J. Virol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12272-020-01299-y","article-title":"Role of specialized pro-resolving lipid mediators and their receptors in virus infection: A promising therapeutic strategy for SARS-CoV-2 cytokine storm","volume":"44","author":"Lee","year":"2021","journal-title":"Arch. Pharm. Res."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/bmjnph-2021-000250","article-title":"Modest effects of dietary supplements during the COVID-19 pandemic: Insights from 445 850 users of the COVID-19 Symptom Study app","volume":"4","author":"Louca","year":"2021","journal-title":"BMJ Nutr. Prev. Health"},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Zapata, B.R., M\u00fcller, J.M., V\u00e1squez, J.E., Ravera, F., Lago, G., Ca\u00f1\u00f3n, E., Casta\u00f1eda, D., Pradenas, M., and Ram\u00edrez-Santana, M. (2021). Omega-3 Index and Clinical Outcomes of Severe COVID-19: Preliminary Results of a Cross-Sectional Study. Int. J. Environ. Res. Public. Health, 18.","DOI":"10.3390\/ijerph18157722"},{"key":"ref_234","first-page":"e10211","article-title":"Icosapent Ethyl\u2014A Successful Treatment for Symptomatic COVID-19 Infection","volume":"12","author":"Berger","year":"2020","journal-title":"Cureus"},{"key":"ref_235","unstructured":"Hackensack Meridian Health (2024, August 25). Feasibility Pilot Clinical Trial of Omega-3 (EPA+DHA) Supplement vs. Placebo for Post-Acute Sequelae of Coronavirus-19 (COVID-19) Recovery Among Health Care Workers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05121766."},{"key":"ref_236","unstructured":"S.L.A. Pharma AG (2024, August 25). A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04335032."},{"key":"ref_237","unstructured":"Hamad Medical Corporation (2024, August 25). Omega-3 Oil Use in COVID-19 Patients in Qatar: A Randomized Controlled Trial, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04836052."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:35:03Z","timestamp":1760031303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":237,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["molecules30102212"],"URL":"https:\/\/doi.org\/10.3390\/molecules30102212","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}